Ceftolozane/tazobactam: place in therapy. Issue 4 (3rd April 2018)

• Record Type: Journal Article
• Authors: Giacobbe, Daniele Roberto; Bassetti, Matteo; De Rosa, Francesco Giuseppe; Del Bono, Valerio; Grossi, Paolo Antonio; Menichetti, Francesco; Pea, Federico; Rossolini, Gian Maria; Tumbarello, Mario; Viale, Pierluigi; Viscoli, Claudio
• Is Part Of: Expert review of anti-infective therapy. Volume 16:Issue 4(2018)
• Page Start: 307
• Page End: 320
• Publication Date: 2018-04-03
• Subjects: Antimicrobial resistance -- MDR -- ceftolozane -- tazobactam -- carbapenem-sparing -- ESBL -- Pseudomonas -- Enterobacteriaceae; Anti-infective agents -- Research -- Periodicals; 616.90461
• DOI: 10.1080/14787210.2018.1447381
• Languages: English
• ISSNs: 1478-7210

Abstract

ABSTRACT: Introduction : Ceftolozane/tazobactam (C/T) is a new antibiotic resulting from the combination of a novel cephalosporin, structurally similar to ceftazidime, with tazobactam, a well-known beta-lactamase inhibitor. C/T remains active against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multi-drug resistant (MDR) P. aeruginosa, and has been recently approved for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). A trial on hospital-acquired pneumonia is ongoing. Areas covered : The place in therapy of C/T is delineated by addressing the following main topics: ( i ) antimicrobial properties; ( ii ) pharmacological properties; ( iii ) results of clinical studies. Expert commentary : C/T is approved for cIAI and cUTI. However, the drug has a special value for clinicians in any kind of infectious localization for two main reasons. The first is that C/T is especially valuable in suspected or documented severe infections due to MDR P. aeruginosa, which is not a rare occurrence in many countries. The second is that C/T may provide an alternative to carbapenems for the treatment of infections caused by ESBL-producers, thus allowing a carbapenem-sparing strategy. Reporting of off -label use is mandatory to increase the body of evidence and the clinicians' confidence in using it for indications other than cIAI and cUTI.